HRP20231581T1 - Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima - Google Patents
Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima Download PDFInfo
- Publication number
- HRP20231581T1 HRP20231581T1 HRP20231581TT HRP20231581T HRP20231581T1 HR P20231581 T1 HRP20231581 T1 HR P20231581T1 HR P20231581T T HRP20231581T T HR P20231581TT HR P20231581 T HRP20231581 T HR P20231581T HR P20231581 T1 HRP20231581 T1 HR P20231581T1
- Authority
- HR
- Croatia
- Prior art keywords
- dengue
- polynucleotide molecule
- polypeptide
- chimera
- mutation
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 229960005486 vaccine Drugs 0.000 title 1
- 208000001490 Dengue Diseases 0.000 claims 61
- 206010012310 Dengue fever Diseases 0.000 claims 61
- 208000025729 dengue disease Diseases 0.000 claims 61
- 239000002157 polynucleotide Substances 0.000 claims 36
- 102000040430 polynucleotide Human genes 0.000 claims 36
- 108091033319 polynucleotide Proteins 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 230000035772 mutation Effects 0.000 claims 19
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 18
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 18
- 230000002163 immunogen Effects 0.000 claims 16
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 13
- 229930024421 Adenine Natural products 0.000 claims 12
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 12
- 229960000643 adenine Drugs 0.000 claims 12
- 230000002238 attenuated effect Effects 0.000 claims 9
- 229940104302 cytosine Drugs 0.000 claims 9
- 229940113082 thymine Drugs 0.000 claims 8
- 101710172711 Structural protein Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 241000710815 Dengue virus 2 Species 0.000 claims 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 239000004296 sodium metabisulphite Substances 0.000 claims 1
- 239000001574 stearyl tartrate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (30)
1. Polinukleotidna molekula koja kodira modificiranu živu, atenuiranu kimernu polipeptidnu molekulu virusa denga-1/denga-2, te polinukleotidna molekula sadrži prvu nukleotidnu sekvencu koja kodira ne strukturne proteine iz modificiranog živog, atenuiranog soja denga-2 virusa PDK-53-V i drugu nukleotidnu sekvencu koja kodira najmanje jedan strukturni protein iz denga-1, naznačena time što polinukleotidna molekula sadrži:
mutaciju adenina u citozin na položaju 3823 koji kodira leucin umjesto izoleucina u polipeptidnoj kimeri virusa denga-1/denga-2 na aminokiselinskom položaju 1243 koji odgovara NS2A-116;
mutaciju adenina u timin na položaju 4407 koji kodira asparaginsku kiselinu umjesto glutaminske kiseline u kimeri polipeptida denga-1/denga-2 na aminokiselinskom položaju 1437 koji odgovara NS2B-92; i
mutaciju adenina u gvanin na položaju 7311.
2. Polinukleotidna molekula prema zahtjevu 1, naznačena time što polinukleotidna molekula koja kodira kimeru polipeptida denga-1/denga-2 nadalje sadrži:
mutaciju citozina u timin na položaju 7148 koji kodira izoleucin umjesto treonina u kimeri polipeptida denga-1/denga-2 na aminokiselinskom položaju 2351 koji odgovara NS4B-108; i
mutaciju gvanina u citozin na položaju 2384 koji kodira alanin umjesto glicina u kimeri polipeptida denga-1/denga-2 na aminokiselinskom položaju 763 koji odgovara E-483.
3. Polinukleotidna molekula prema zahtjevu 1, naznačena time što polinukleotidna molekula koja kodira kimeru polipeptida denga-1/denga-2 sadrži polinukleotid predstavljen sa SEQ ID NO: 13.
4. Polinukleotidna molekula prema zahtjevu 1 ili 3, naznačena time što polinukleotidna molekula kodira kimeru polipeptida denga-1/denga-2 predstavljenu sa SEQ ID NO: 3.
5. Polipeptidna molekula kodirana polinukleotidnom molekulom prema bilo kojem od zahtjeva 1-4.
6. Kimera denga-1/denga-2,
koja sadrži polipeptidnu molekulu prema zahtjevu 5, ili
predstavljena sa polinukleotidnom molekulom prema bilo kojem od zahtjeva 1-4.
7. Farmaceutski pripravak, naznačen time što sadrži polinukleotidnu molekulu prema bilo kojem od zahtjeva 1-4, polipeptidnu molekulu prema zahtjevu 5, ili kimeru denga-1/denga-2 prema zahtjevu 6, te farmaceutski prihvatljivu pomoćnu tvar.
8. Farmaceutski pripravak prema zahtjevu 7, naznačen time što se koristi kao lijek.
9. Farmaceutski pripravak prema zahtjevu 7, naznačen time što se koristi u postupku indukcije imunološkog odgovora kod subjekta koji obuhvaća davanje farmaceutski prihvatljive količine pripravka.
10. Vektor, naznačen time što kodira polinukleotidnu molekulu prema bilo kojem od zahtjeva 1-4.
11. Stanična linija, naznačena time što sadrži polinukleotidnu molekulu prema bilo kojem od zahtjeva 1-4 ili vektor prema zahtjevu 10.
12. Imunogeni pripravak, naznačen time što sadrži kimeru denga-1/denga-2 predstavljenu polinukleotidnom molekulom prema bilo kojem od zahtjeva 1-4 i farmaceutski prihvatljiv nosač.
13. Imunogeni pripravak prema zahtjevu 12, koji nadalje sadrži kimeru denga-3/denga-2 predstavljenu polinukleotidnom molekulom koji kodira kimeru polipeptida denga-3/denga-2, pri čemu polinukleotidna molekula sadrži prvu nukleotidnu sekvencu koja kodira ne strukturne proteine iz modificiranog živog, atenuiranog soja virusa denga-2 PDK-53-V, i drugu nukleotidnu sekvencu koja kodira najmanje jedan strukturni protein iz denga-3, pri čemu polinukleotidna molekula sadrži:
mutaciju adenina u timin na položaju 1603 koji kodira serin umjesto treonina u kimeri polipeptida denga-3/denga-2 na aminokiselinskom položaju 503 koji odgovara E-223; i
mutaciju adenina u gvanin na položaju 7620.
14. Imunogeni pripravak prema zahtjevu 13, naznačen time što polinukleotidna molekula koja kodira kimeru polipeptida denga-3/denga-2 nadalje sadrži mutaciju gvanina u adenin na položaju 6436 koji kodira asparagin umjesto asparaginske kiseline u kimeri polipeptida denga-3/denga-2 na aminokiselinskom položaju 2114 koji odgovara NS4A-23.
15. Imunogeni pripravak prema zahtjevu 13, naznačen time što polinukleotidna molekula koja kodira kimeru polipeptida denga-3/denga-2 sadrži polinukleotid predstavljen sa SEQ ID NO: 15.
16. Imunogeni pripravak prema zahtjevu 13 ili 15, naznačen time što polinukleotidna molekula kodira kimeru polipeptida denga-3/denga-2 predstavljenu sa SEQ ID NO: 9.
17. Imunogeni pripravak prema bilo kojem od zahtjeva 12 do 16, naznačen time što nadalje sadrži kimeru denga-4/denga-2 predstavljenu polinukleotidnom molekulom koja kodira kimeru polipeptida denga-4/denga-2, pri čemu polinukleotidna molekula sadrži prvu nukleotidnu sekvencu koja kodira ne strukturne proteine iz modificiranog živog, atenuiranog soja virusa denga-2 PDK-53-V, i drugu nukleotidnu sekvencu koja kodira najmanje jedan strukturni protein iz denga-4, pri čemu polinukleotidna molekula sadrži:
mutaciju adenina u timin na položaju 225;
mutaciju adenina u gvanin na položaju 3674 koji kodira glicin umjesto asparaginske kiseline u kimeri polipeptida denga-4/denga-2 na aminokiselinskom položaju 1193 koji odgovara NS2A-66;
mutaciju citozina u timin na položaju 5391;
mutaciju citozina u timin na položaju 6437 koji kodira valin umjesto alanina u kimeri polipeptida denga-4/denga-2 na aminokiselinskom položaju 2114 koji odgovara NS4A-21,
mutaciju adenina u citozin na položaju 9750, i
po izboru mutaciju timina u citozin na položaju 7026, i po izboru mutaciju adenina u gvanin na položaju 3773 koji kodira arginin umjesto lizina u kimeri polipeptida denga-4/denga-2 na aminokiselinskom položaju 1226 koja odgovara NS2A-99.
18. Imunogeni pripravak prema zahtjevu 17, naznačen time što polinukleotidna molekula koja kodira kimeru polipeptida denga-4/denga-2 nadalje sadrži mutaciju citozina u timin na položaju 7538 koji kodira fenilalanin umjesto serina u kimeri polipeptida denga-4/denga-2 na aminokiselinskom položaju 2481 koji odgovara NS4B-238.
19. Imunogeni pripravak prema zahtjevu 17, naznačen time što polinukleotidna molekula koja kodira kimeru polipeptida denga-4/denga-2 sadrži polinukleotid predstavljen sa SEQ ID NO: 16.
20. Imunogeni pripravak prema bilo kojem od zahtjeva 17 ili 19, naznačen time što polinukleotidna molekula kodira kimeru polipeptida denga-4/denga-2 predstavljenu sa SEQ ID NO: 12.
21. Imunogeni pripravak prema bilo kojem od zahtjeva 12 do 20, naznačen time što nadalje sadrži modificirani živi, atenuirani soj denga-2 virusa PDK-53-V predstavljen polinukleotidnom molekulom koja kodira polipeptidnu molekulu modificiranog živog, atenuiranog soja virusa denga-2 PDK-53-V, pri čemu polinukleotidna molekula sadrži:
mutaciju adenina u gvanin na položaju 592 koji kodira glutaminsku kiselinu umjesto lizina u polipeptidnoj molekuli na aminokiselinskom položaju 166 koji odgovara prM-52; i
mutaciju adenina u gvanin na položaju 8803 koji kodira valin umjesto izoleucina u polipeptidnoj molekuli na položaju aminokiseline 2903 koji odgovara NS5-412.
22. Imunogeni pripravak prema zahtjevu 21, naznačen time što polinukleotidna molekula koja kodira modificiranu živu, atenuiranu polipeptidnu molekulu PDK-53-V soja virusa denga-2 dalje sadrži mutaciju gvanina u citozin na položaju 6481 koji kodira prolin umjesto alanina u polipeptidnoj molekuli na položaju aminokiseline 2129 koja odgovara NS4A-36.
23. Imunogeni pripravak prema zahtjevu 21, naznačen time što polinukleotidna molekula koja kodira polipeptidnu molekulu modificiranog živog, atenuiranog soja virusa denga-2 PDK-53-V sadrži polinukleotid predstavljen sa SEQ ID NO: 14.
24. Imunogeni pripravak prema zahtjevu 21 ili 23, naznačen time što polinukleotidna molekula kodira modificiranu, živu atenuiranu polipeptidnu molekulu PDK-53-V soja virusa denga-2 predstavljenu sa SEQ ID NO: 6.
25. Imunogeni pripravak prema bilo kojem od zahtjeva 12 do 24, naznačen time što pripravak sadrži sva četiri serotipa denga virusa, što je četverovalentni pripravak.
26. Imunogeni pripravak prema bilo kojem od zahtjeva 12 do 25, naznačen time što nadalje sadrži imunogeni pripravak protiv drugih flavivirusa kao što je virus Zapadnog Nila ili virus japanskog encefalitisa.
27. Pripravak koji sadrži jednu ili više kimera denga-1/denga-2 prema zahtjevu 6 i farmaceutski prihvatljiv nosač.
28. Pripravak prema zahtjevu 27, naznačen time što je pripravak četverovalentni pripravak virusa denga groznice sposoban inducirati imunološki odgovor kod subjekta protiv sva četiri serotipa virusa denga groznice.
29. Vektor prema zahtjevu 10, naznačen time što je vektor plazmidni vektor.
30. Vektor prema zahtjevu 10, naznačen time što je vektor cDNA infektivni klon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361800204P | 2013-03-15 | 2013-03-15 | |
EP22182269.5A EP4129330B1 (en) | 2013-03-15 | 2014-03-12 | Compositions and methods for dengue virus chimeric constructs in vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231581T1 true HRP20231581T1 (hr) | 2024-03-15 |
Family
ID=50678274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231581TT HRP20231581T1 (hr) | 2013-03-15 | 2014-03-12 | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
Country Status (32)
Country | Link |
---|---|
US (5) | US9783579B2 (hr) |
EP (5) | EP2968516B1 (hr) |
JP (2) | JP6818548B2 (hr) |
KR (3) | KR102626270B1 (hr) |
CN (5) | CN111778263A (hr) |
AR (2) | AR095598A1 (hr) |
AU (2) | AU2014235476B2 (hr) |
CA (4) | CA3177574A1 (hr) |
CR (1) | CR20150569A (hr) |
DK (1) | DK4129330T3 (hr) |
DO (1) | DOP2015000232A (hr) |
EC (1) | ECSP23013715A (hr) |
ES (2) | ES2965652T3 (hr) |
FI (2) | FI3539565T3 (hr) |
FR (1) | FR22C1064I1 (hr) |
HK (1) | HK1220359A1 (hr) |
HR (1) | HRP20231581T1 (hr) |
HU (2) | HUE061507T2 (hr) |
LT (1) | LT4129330T (hr) |
MX (5) | MX2015012893A (hr) |
MY (1) | MY187796A (hr) |
NL (1) | NL301223I2 (hr) |
NZ (1) | NZ630869A (hr) |
PE (2) | PE20160027A1 (hr) |
PH (1) | PH12015502120A1 (hr) |
PL (1) | PL3539565T3 (hr) |
PT (1) | PT3539565T (hr) |
SG (3) | SG11201507460PA (hr) |
SI (1) | SI4129330T1 (hr) |
TW (3) | TW202144573A (hr) |
UY (1) | UY35489A (hr) |
WO (1) | WO2014150939A2 (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507460PA (en) * | 2013-03-15 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for dengue virus chimeric constructs in vaccines |
US10004795B2 (en) * | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
SG11201804317YA (en) * | 2015-11-27 | 2018-06-28 | The Chemo Sero Therapeutic Res Institute | Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens |
WO2017179017A1 (en) * | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
BR112021003962A2 (pt) | 2018-09-05 | 2021-05-25 | Takeda Vaccines, Inc. | dose unitária de vacina contra dengue e sua administração |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
JP2023516009A (ja) | 2020-02-27 | 2023-04-17 | タケダ ワクチン,インコーポレイテッド | ウイルス調製物から宿主細胞dnaを取り除く方法 |
WO2021173597A1 (en) * | 2020-02-28 | 2021-09-02 | Merck Sharp & Dohme Corp. | Dengue serotype specific rt-pcr multiplex assay |
WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
WO2024108087A1 (en) | 2022-11-18 | 2024-05-23 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5276941A (en) | 1975-12-23 | 1977-06-28 | Ito Masato | Method of conversing infrared rays |
US4810092A (en) | 1986-02-21 | 1989-03-07 | Midac Corporation | Economical spectrometer unit having simplified structure |
JPH0768267B2 (ja) | 1986-06-05 | 1995-07-26 | 財団法人阪大微生物病研究会 | フラビウイルス抗原 |
JPH084508B2 (ja) | 1987-09-16 | 1996-01-24 | 国立予防衛生研究所長 | 組み換えワクチニアウイルス |
JP2511494B2 (ja) | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
IL91304A0 (en) | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5494671A (en) | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
ATE197607T1 (de) | 1991-09-19 | 2000-12-15 | Us Health | Chimäre und/oder wachstumgehemmte flaviviren |
JPH05276941A (ja) | 1992-02-28 | 1993-10-26 | Nippon Zeon Co Ltd | フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法 |
ATE227584T1 (de) | 1995-05-24 | 2002-11-15 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
WO1996040933A1 (en) * | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
RU2208635C2 (ru) | 1997-10-08 | 2003-07-20 | ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ | Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита |
JP4489943B2 (ja) | 1998-06-04 | 2010-06-23 | アメリカ合衆国 | フラビウイルス感染の予防のための核酸ワクチン |
AU1813901A (en) * | 1999-12-01 | 2001-06-12 | Oravax, Inc | Chimeric flavivirus vaccines |
AU3844101A (en) * | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
DK1159968T3 (da) * | 2000-05-30 | 2009-02-23 | Univ Mahidol | Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning |
CA2440593A1 (en) | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
KR20080018271A (ko) | 2005-06-17 | 2008-02-27 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 2 균주 |
WO2006134433A1 (en) * | 2005-06-17 | 2006-12-21 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
KR20070017759A (ko) | 2005-08-08 | 2007-02-13 | 삼성전자주식회사 | 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법 |
AU2006280144B2 (en) * | 2005-08-10 | 2012-06-14 | Sanofi Pasteur Biologics, Llc | Vaccination against dengue virus infection |
US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
US8337860B2 (en) * | 2006-08-15 | 2012-12-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Development of dengue virus vaccine components |
US8541377B2 (en) | 2007-07-13 | 2013-09-24 | Florida Gulf Coast University | Optimized dengue virus entry inhibitory peptide (DN81) |
WO2009134717A1 (en) * | 2008-04-30 | 2009-11-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
SG157244A1 (en) | 2008-05-15 | 2009-12-29 | Mp Biomedicals Asia Pacific Pte Ltd | Point of care test for the detection of exposure or immunity to dengue virus |
JP5276941B2 (ja) | 2008-09-24 | 2013-08-28 | 株式会社村田製作所 | 大変位アクチュエータ |
WO2010085358A2 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
CN107913406A (zh) | 2009-06-01 | 2018-04-17 | 武田疫苗公司 | 施用针对登革病毒的疫苗的组合物和方法 |
CN101560520A (zh) * | 2009-06-04 | 2009-10-21 | 中国疾病预防控制中心病毒病预防控制所 | 乙脑/登革嵌合病毒及其应用 |
BRPI0904020B8 (pt) * | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
CA2915027A1 (en) | 2012-06-10 | 2013-12-19 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
CN104812408A (zh) | 2012-07-24 | 2015-07-29 | 赛诺菲巴斯德有限公司 | 用于防止登革热病毒感染的疫苗组合物 |
MY197723A (en) | 2012-07-24 | 2023-07-10 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
TW201428101A (zh) * | 2012-11-08 | 2014-07-16 | Inviragen Inc | 登革熱病毒血清型4型之建構物的組成物、方法及用途 |
EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
SG11201507460PA (en) | 2013-03-15 | 2015-10-29 | Takeda Vaccines Inc | Compositions and methods for dengue virus chimeric constructs in vaccines |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
WO2017005654A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
US10004795B2 (en) | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
WO2017179017A1 (en) * | 2016-04-13 | 2017-10-19 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
JP7261239B2 (ja) | 2017-10-16 | 2023-04-19 | セラム インスティチュート オブ インディア プライベイト リミテッド | 弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法 |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2014
- 2014-03-12 SG SG11201507460PA patent/SG11201507460PA/en unknown
- 2014-03-12 CN CN202010617988.1A patent/CN111778263A/zh active Pending
- 2014-03-12 SG SG10201913435TA patent/SG10201913435TA/en unknown
- 2014-03-12 AU AU2014235476A patent/AU2014235476B2/en active Active
- 2014-03-12 PE PE2015001953A patent/PE20160027A1/es unknown
- 2014-03-12 LT LTEP22182269.5T patent/LT4129330T/lt unknown
- 2014-03-12 PE PE2021000217A patent/PE20211814A1/es unknown
- 2014-03-12 PT PT191684752T patent/PT3539565T/pt unknown
- 2014-03-12 MX MX2015012893A patent/MX2015012893A/es active IP Right Grant
- 2014-03-12 JP JP2016501585A patent/JP6818548B2/ja active Active
- 2014-03-12 NZ NZ630869A patent/NZ630869A/en unknown
- 2014-03-12 SI SI201432055T patent/SI4129330T1/sl unknown
- 2014-03-12 HU HUE19168475A patent/HUE061507T2/hu unknown
- 2014-03-12 EP EP14722014.9A patent/EP2968516B1/en active Active
- 2014-03-12 CA CA3177574A patent/CA3177574A1/en active Pending
- 2014-03-12 EP EP22204593.2A patent/EP4183411A1/en active Pending
- 2014-03-12 CA CA3177572A patent/CA3177572A1/en active Pending
- 2014-03-12 DK DK22182269.5T patent/DK4129330T3/da active
- 2014-03-12 MY MYPI2015002317A patent/MY187796A/en unknown
- 2014-03-12 CA CA2903231A patent/CA2903231A1/en active Pending
- 2014-03-12 KR KR1020227013084A patent/KR102626270B1/ko active IP Right Grant
- 2014-03-12 KR KR1020247001384A patent/KR20240014580A/ko active Application Filing
- 2014-03-12 KR KR1020157029897A patent/KR102389908B1/ko active IP Right Grant
- 2014-03-12 PL PL19168475.2T patent/PL3539565T3/pl unknown
- 2014-03-12 EP EP20154012.7A patent/EP3689374B1/en active Active
- 2014-03-12 CN CN202110718703.8A patent/CN113637694A/zh active Pending
- 2014-03-12 SG SG10201913387XA patent/SG10201913387XA/en unknown
- 2014-03-12 EP EP22182269.5A patent/EP4129330B1/en active Active
- 2014-03-12 CN CN201480028001.5A patent/CN105451763B/zh active Active
- 2014-03-12 ES ES22182269T patent/ES2965652T3/es active Active
- 2014-03-12 FI FIEP19168475.2T patent/FI3539565T3/fi active
- 2014-03-12 CN CN202110718694.2A patent/CN113637693A/zh active Pending
- 2014-03-12 HR HRP20231581TT patent/HRP20231581T1/hr unknown
- 2014-03-12 CA CA3166063A patent/CA3166063A1/en active Pending
- 2014-03-12 WO PCT/US2014/024603 patent/WO2014150939A2/en active Application Filing
- 2014-03-12 ES ES20154012T patent/ES2933970T3/es active Active
- 2014-03-12 EP EP19168475.2A patent/EP3539565B1/en active Active
- 2014-03-12 CN CN202110723336.0A patent/CN113637086A/zh active Pending
- 2014-03-13 US US14/209,808 patent/US9783579B2/en active Active
- 2014-03-14 TW TW110111747A patent/TW202144573A/zh unknown
- 2014-03-14 TW TW108114540A patent/TWI726312B/zh active
- 2014-03-14 TW TW103109624A patent/TWI733646B/zh active
- 2014-03-17 UY UY35489A patent/UY35489A/es active IP Right Grant
- 2014-03-17 AR ARP140101223A patent/AR095598A1/es unknown
-
2015
- 2015-09-11 DO DO2015000232A patent/DOP2015000232A/es unknown
- 2015-09-14 PH PH12015502120A patent/PH12015502120A1/en unknown
- 2015-09-14 MX MX2019003602A patent/MX2019003602A/es unknown
- 2015-09-14 MX MX2023000354A patent/MX2023000354A/es unknown
- 2015-09-14 MX MX2023000349A patent/MX2023000349A/es unknown
- 2015-09-14 MX MX2023000353A patent/MX2023000353A/es unknown
- 2015-10-15 CR CR20150569A patent/CR20150569A/es unknown
-
2016
- 2016-07-15 HK HK16108390.1A patent/HK1220359A1/zh unknown
-
2017
- 2017-04-20 US US15/492,981 patent/US10449231B2/en active Active
-
2019
- 2019-06-05 JP JP2019105307A patent/JP7050031B2/ja active Active
- 2019-08-16 AU AU2019216724A patent/AU2019216724C1/en active Active
- 2019-09-05 US US16/561,755 patent/US20200061151A1/en not_active Abandoned
-
2021
- 2021-09-17 US US17/478,537 patent/US20220062375A1/en active Pending
- 2021-10-06 AR ARP210102772A patent/AR123702A2/es unknown
-
2022
- 2022-12-12 US US18/064,775 patent/US11931399B2/en active Active
- 2022-12-16 FR FR22C1064C patent/FR22C1064I1/fr active Active
-
2023
- 2023-02-24 EC ECSENADI202313715A patent/ECSP23013715A/es unknown
- 2023-03-08 NL NL301223C patent/NL301223I2/nl unknown
- 2023-06-20 HU HUS2300022C patent/HUS2300022I1/hu unknown
- 2023-06-27 FI FIC20230021C patent/FIC20230021I1/fi unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231581T1 (hr) | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima | |
JP2016501015A5 (ja) | デングウイルス血清型4(den−4)構築物に関する組成物、方法および使用 | |
JP2016513970A5 (hr) | ||
CA2991002C (en) | Vaccine against rsv | |
EP3319634B1 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
HRP20231496T1 (hr) | Cistein proteaza | |
Costa et al. | DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice | |
NZ630839A (en) | Compositions, methods and uses for dengue virus serotype-4 constructs | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
HRP20221089T1 (hr) | Optimizirani geni faktora viii | |
HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
US9878031B2 (en) | Compositions, methods of administration and uses for trivalent dengue virus formulations | |
RU2009121566A (ru) | Стабилизация вакцин лиофилизацией | |
AU2008203442A1 (en) | Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus | |
JP2019505567A5 (hr) | ||
Yang et al. | Molecular cloning and nucleotide sequences of cDNAs for histone H1 and H2B variants from wheat. | |
JP2017526366A5 (hr) | ||
DK1947175T3 (da) | Sekvens af nukleotider og peptider GSE 24,2 af dyskerin, der kan fremkalde telomeraseaktivitet, fremgangsmåde til fremstilling deraf, terapeutiske sammensætninger og anvendelser deraf | |
RU2019113940A (ru) | Мозаичные вакцины от вируса ящура серотипа а | |
TH2001003757A (th) | องค์ประกอบวัคซีนสำหรับไวรัสโรคเท้าและปากประเภท a | |
RU2021109330A (ru) | Химерные вакцины на основе вирусов родов flavivirus и lyssavirus | |
TH1901000566A (th) | รีคอมบิแนนท์เด็งกี่-4สายพันธุ์1036pdk40และโคลนติดเชื้อไวรัสอ่อนฤทธิ์เด็งกี่-4ที่ประกอบด้วยรีคอมบิแนนท์เด็งกี่-4สายพันธุ์1036pdk40นั้น | |
TH170668A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน |